Arkolith/Insider Trading/PHIO/Form 4

Bitterman Robert J

President & CEO, DirectorPhio Pharmaceuticals Corp. (PHIO) · full profile →Form 4 · filed Oct 3, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 1, 2023Tax withholding(F)917$1.51$1K18K

Transaction Codes

F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-051706) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML